Form 8-K - Current report:
SEC Accession No. 0001564590-21-036365
Filing Date
2021-07-13
Accepted
2021-07-13 08:15:27
Documents
14
Period of Report
2021-07-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-8k_20210713.htm   iXBRL 8-K 37048
2 EX-99.1 abio-ex991_6.htm EX-99.1 22559
3 GRAPHIC gpolna3mi5dd000001.jpg GRAPHIC 202155
  Complete submission text file 0001564590-21-036365.txt   474176

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA abio-20210713.xsd EX-101.SCH 5796
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE abio-20210713_lab.xml EX-101.LAB 19478
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abio-20210713_pre.xml EX-101.PRE 11645
7 EXTRACTED XBRL INSTANCE DOCUMENT abio-8k_20210713_htm.xml XML 3525
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 211086838
SIC: 2835 In Vitro & In Vivo Diagnostic Substances